Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.

Abstract excerpt

KRAS mutations are prevalent in lung cancer, but KRASG12C inhibitors exhibit limited efficacy, partly due to metabolic adaptations, such as enhanced glutathione (GSH) metabolism and increased glycolysis. Glutathione S-transferase zeta 1 (GSTZ1) is a metabolic enzyme that regulates cell metabolism; however, its role in KRAS-driven lung cancer remains underexplored. We recently reported that targeting GSTZ1...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma, Non-Small-Cell Lung
• Share to Cell Line, Tumor